Search Results - christophe+marchand

3 Results Sort By:
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Abstract: Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors...
Published: 4/8/2024   |   Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier
Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics
Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase
Abstract: Integrase strand transfer inhibitors (“INSTIs”) are currently in use as a component of prophylactic antiretroviral therapy for preventing HIV-1 infection from progressing to AIDS. Three INSTIs are approved by the FDA for inclusion in antiretroviral regiments: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Clinicians have already...
Published: 5/22/2024   |   Inventor(s): Xue Zhao, Terrence Burke, Yves Pommier, Stephen Hughes, Mathieu Metifiot, Stephen Smith, Barry Johnson, Christophe Marchand
Keywords(s): dolutegravir, drug resistant HIV, elvitegravir, HIV therapy, Integrase, raltegravir, strand transfer
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
Abstract: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that playings a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates...
Published: 4/8/2024   |   Inventor(s): Christophe Marchand, Lin-kun An, Yves Pommier
Keywords(s): CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics